No products in the cart.
Pre-made Dusigitumab benchmark antibody ( Whole mAb, anti-IGF1;IGF2 therapeutic antibody, Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-160
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Dusigitumab biosimilar, Whole mAb, Anti-IGF1;IGF2 Antibody: Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2.[1] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.
| Products Name (INN Index) | Pre-Made Dusigitumab biosimilar, Whole mAb, Anti-IGF1;IGF2 Antibody: Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 therapeutic antibody |
|---|---|
| INN Name | Dusigitumab |
| Target | IGF1&IGF2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | MedImmune |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Breast cancer,Liver cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IGF1&IGF2 |
| Package |
Previous slide
Next slide
